ACA
EIGR

Apis Capital Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Apis Capital Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,333
Closed -$267K – 38
2021
Q3 		$267K Buy
+1,333
New +$317K 0.25% 34

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Apis Capital Advisors's EIGR Position: Q4 2021 in Review

Apis Capital Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 1,333 shares — an estimated $267K sold.

Apis Capital Advisors first reported a position in EIGR in Q3 2021 and held it in 1 quarter. The position peaked at $267K in Q3 2021. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • Apis Capital Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Apis Capital Advisors sold 1,333 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $267K.
  • Apis Capital Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2021 and held it in 1 quarter.
  • Apis Capital Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $267K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Apis Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.